TDC
AUPH icon

Thompson Davis & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Thompson Davis & Co’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250
Closed -$1K – 628
2017
Q4 		$1K Hold
250
– – ﹤0.01% 630
2017
Q3 		$2K Buy
+250
New +$1.58K ﹤0.01% 978

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Thompson Davis & Co's AUPH Position: Q1 2018 in Review

Thompson Davis & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2018, closing a stake of 250 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in AUPH in Q3 2017 and held it in 2 quarters. The position peaked at $2K in Q3 2017. 64 funds tracked by Wall St. Rank hold AUPH as of Q1 2018.

  • Thompson Davis & Co reported no remaining Aurinia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Aurinia Pharmaceuticals shares in Q1 2018, an estimated $1K.
  • Thompson Davis & Co first reported a position in Aurinia Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Thompson Davis & Co's Aurinia Pharmaceuticals position peaked at $2K in Q3 2017.
  • 64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.